Advertisement

Topics

Merck’s Keytruda Receives FDA Approval for Treatment of Refractory or Relapsed Primary Mediastinal Large B-Cell Lymphoma

11:07 EDT 14 Jun 2018 | Speciality Pharma Journal

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA®, the company’s anti-PD-1 therapy, for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more prior …

Original Article: Merck’s Keytruda Receives FDA Approval for Treatment of Refractory or Relapsed Primary Mediastinal Large B-Cell Lymphoma

NEXT ARTICLE

More From BioPortfolio on "Merck’s Keytruda Receives FDA Approval for Treatment of Refractory or Relapsed Primary Mediastinal Large B-Cell Lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...